Childhood acute lymphoblastic leukemia treatment faces a striking paradox: while cutting-edge immunotherapies like CAR T-cells offer unprecedented cure rates in developed nations, most young patients globally cannot access these life-saving advances. This disparity underscores how medical breakthroughs mean little without equitable distribution systems. Contemporary ALL treatment has transformed from simple chemotherapy to sophisticated risk-adapted protocols incorporating molecular diagnostics, targeted monoclonal antibodies, and engineered immune cell therapies. CAR T-cell treatment, where patient T-cells are genetically modified to hunt cancer cells, demonstrates particular efficacy in relapsed cases previously considered terminal. Multi-phase chemotherapy protocols now achieve remission rates exceeding 90% when combined with precision diagnostics using immunophenotyping and cytogenetic analysis. However, this therapeutic revolution remains concentrated in high-income healthcare systems. The Brazilian experience illuminates this global challenge, where despite being Latin America's largest economy, many pediatric oncology centers lack access to advanced immunotherapies and molecular diagnostic capabilities. This treatment gap perpetuates survival disparities that contradict the universal nature of childhood cancer. The review emphasizes that technological advances alone cannot solve pediatric ALL - systematic healthcare infrastructure development, pharmaceutical pricing reform, and international cooperation are equally critical. While CAR T-cells and monoclonal antibodies represent genuine therapeutic breakthroughs, their impact will remain limited until healthcare equity catches up with medical innovation.